All Data
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
In a meeting, Subject Expert Committee (SEC) on COVID-19 at the CDSCO, deliberated on the application and asked the firm to resubmit a revised protocol as it was not satisfied with the data of Phase II trials submitted by the company.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
Details:
Upon regulatory approval in India, RDIF will supply to drugmaker Dr Reddy's 100 million doses of the vaccine, the firm said last month.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Indian Council of Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
India’s first phase 3 efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted in India. Trial volunteers will receive two intramuscular injections of Covaxin, about 28 days apart.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Secnidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Solosec
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The Solosec® sNDA is based, in part, on trial results that showed a clinically and statistically significant response rate, or microbiological cure, in patients treated with Solosec® as compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Government of Bangladesh
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 05, 2020
Details:
5 million doses of ChAdOx1 nCoV-19 per month would be purchased through Bangladesh’s drug maker, Beximco Pharmaceuticals. Serum Institute would provide the vaccine at a price similar to that which India pays.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir,Umifenovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Results from the “FAITH” combination trial shows that addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate COVID-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 29, 2020
Details:
The expansion brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
Drugs Controller General of India (DCGI) to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
The vaccine candidate AZD 1222 uses a non-replicating chimpanzee adenovirus to deliver a SARS-CoV-2 spike protein to induce an immune response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Beximco Pharmaceuticals Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 28, 2020
Details:
Beximco will be the exclusive supplier of the vaccine in Bangladesh and will facilitate the needs of the Government of Bangladesh by offering the opportunity for it to reserve the desired quantities for priority supply at prices to be agreed between the Government and SII.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
